ClinicalTrials.gg
RecruitingNCT06936735Updated Jun 2, 2026

A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of HS-20108 Monotherapy in Advanced Solid Tumor, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Primary conditionnone(registry's first term: Small Cell Lung Carcinoma)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Small Cell Lung Carcinoma, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
502
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.

Read the detailed description

This is a multicenter, open-label Phase I clinical study to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors. The study consists of Phase Ia (dose escalation) and Phase Ib (dose expansion). In Phase Ia, dose escalation in monotherapy and combination therapy will conduct to identify the maximum tolerated dose (MTD) in patients with advanced solid tumors. In Phase Ib, potential indications (such as small cell lung cancer or neuroendocrine carcinoma) will be selected for the early proof-of-concept study of HS-20108 at different doses in monotherapy and combination therapy based on the study data from Phase Ia, the translational medicine research data and R\&D progress in the field.

02

Conditions studied

  • Advanced Solid Tumor

Browse trials for

Keywords

  • small cell lung cancer
  • neuroendocrine carcinoma
03

In context

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged more than or equal to (≥) 18 years.
  2. Participants with confirmed advanced solid tumors.
  3. At least one in accordance with 1.1
  4. Fresh or available for submission.
  5. (ECOG) performance status: 0\~1.
  6. Estimated >12 weeks.
  7. Reproductive-age women agree to use adequate and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.
  8. Females must have evidence of non-.
  9. Signed and dated Form.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following:

    Having received cytotoxic chemotherapy agents, drugs, Chinese medicine treatment with anti-tumor indications, or other anti-tumor therapy (including endocrine therapy, molecular targeted therapy, or biotherapy) within 14 days before the first dose of study treatment.

    Having received macromolecular anti-tumor drug therapy (including immunotherapy, such as monoclonal antibody drugs and bispecific antibody drugs) within 28 days before the first dose of study treatment.

    Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.

    Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.

  2. Inadequate bone marrow reserve or serious organ dysfunction.
  3. Uncontrolled pleural effusion or ascites or pericardial effusion.
  4. Known and untreated, or active central nervous system .
  5. Active diseases or active infectious disease
  6. Known to have interstitial pneumonia or immune pneumonia
  7. History of severe allergic reaction, serious transfusion reactions or Allergy to any component of HS-20108
  8. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator.
  9. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator.
  10. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.
  11. History of neuropathy or mental disorders, including epilepsy and dementia.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
502 participants (estimated)

Study arms

  • Experimental
    HS-20108 Ia

    Phase Ia Dose Escalation

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108 Ib Cohort1

    Phase Ib Dose Expansion Cohort 1: Participants with small cell lung cancer will receive varying doses of HS-20108

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108 Ib Cohort2

    Phase Ib Dose Expansion Cohort 2: Participants with neuroendocrine carcinoma will receive varying doses of HS-20108

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108 Ib Cohort3

    Phase Ib Dose Expansion Cohort 3: Participants with other advanced solid tumors will receive varying doses of HS-20108

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108 and Adebrelimab Ia&Ib

    Phase Ia Dose Escalation Phase Ib Dose Expansion

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108 and SHR-7787 Ia &Ib

    Phase Ia Dose Escalation Phase Ib Dose Expansion

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108、Adebrelimab and SHR-7787 Ia &Ib

    Phase Ia Dose Escalation Phase Ib Dose Expansion

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108 and Cisplatin / Carboplatin Ia&Ib

    Phase Ia Dose Escalation Phase Ib Dose Expansion

    Drug: HS-20108 Monotherapy

  • Experimental
    HS-20108、Adebrelimab and Cisplatin / Carboplatin Ia&Ib

    Phase Ib Dose Expansion

    Drug: HS-20108 Monotherapy

Interventions

  • DrugHS-20108 Monotherapy

    Intravenous (IV) Infusion

06

What researchers measure

Primary outcomes

  1. MTD or MAD of HS-20108

    the maximum tolerated dose or maximum appropriate dose

    Time frame: up to approximately 48 months

Secondary outcomes

  1. Incidence of adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant administered an investigational product, which may present with symptoms, signs, disease, or laboratory abnormalities, but do not necessarily have a causality with the investigational product.

    Time frame: up to approximately 48 months

  2. Objective response rate (ORR) assessed by investigator

    ORR is defined as the percentage of patients with a CR or PR that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.

    Time frame: up to approximately 48 months.

  3. Disease Control Rate (DCR)

    Disease control was defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks).

    Time frame: up to approximately 48 months.

  4. Duration of response (DOR)

    Duration of response assessed by RECIST 1.1. Duration of response was defined as the time from when the criteria for CR or PR were first met to the occurrence of an objective disease progression (PD) or death.

    Time frame: up to approximately 48 months.

  5. Progression-free survival (PFS)

    Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was defined as the time from date of first dose until the documentation of objective PD or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.

    Time frame: up to approximately 48 months.

  6. overall survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: up to approximately 48 months.

  7. Observed maximum plasma concentration (Cmax) of HS-20108

    Cmax of HS-20108 (administered either as a monotherapy or in combination)

    Time frame: up to approximately 48 months.

  8. Area Under the Plasma Concentration-Time Curve (AUC) of HS-20108

    AUC of HS-20108 (administered either as a monotherapy or in combination)

    Time frame: up to approximately 48 months.

  9. Immunogenicity (administered either as a monotherapy or in combination)

    Immunogenicity

    Time frame: up to approximately 48 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Aug 2028, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 20, 2025
StartActual
May 29, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Feb 28, 2029
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06936735
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
May 29, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Jun 2, 2026

Study contacts

Jie Chen, Doctor
Contact
Chen0jie@hotmail.com
+8613660217442

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion